Sangamo Therapeutics Highlights Presentation At Annual Symposium of the Society for the Study of Inborn Errors of Metabolism Evaluating SB-913 Which Showed Early Data From Cohorts 1, 2, Enrollment Of Cohort 3 Recently Completed
luke@benzinga.com